Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01773928 · ClinicalTrials.gov registry record · Phase 3
Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)
A Phase 3 study, sponsored by Alachua Government Services.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,928
- Enrollment target
NCT01773928 is a Phase 3 study that has completed, run by Alachua Government Services. The registered enrollment target is 1,928 participants.
The verdict
NCT01773928, a Phase 3 study, has completed, sponsored by Alachua Government Services.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,928 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a Vero cell-derived trivalent seasonal influenza vaccine produced by the modified manufacturing process: 1. induces immune responses comparable to that produced by the current manufacturing process 2. has an acceptable safety profile compared to a licensed trivalent seasonal influenza vaccine 3. demonstrates consistency of immune response among three different lots.
Interventions
- BIOLOGICAL Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)
- BIOLOGICAL VCIV manufactured with the current manufacturing process (VCIV current)
- BIOLOGICAL Fluzone®, licensed trivalent influenza vaccine (TIV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,928 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01773928
The ClinicalTrials.gov registry entry for NCT01773928 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,928 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alachua Government Services, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified) is the first listed.
NCT01773928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01773928 about?
NCT01773928 is a clinical study titled "Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)". The purpose of this study is to determine if a Vero cell-derived trivalent seasonal influenza vaccine produced by the modified manufacturing process: 1. induces immune responses comparable to that produced by the current manufacturing process 2. has an acceptable safety profile compared to a licens...
What is the current status of trial NCT01773928?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,928 participants. The study started on 2013-01. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01773928?
The interventions under investigation include: Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified) (BIOLOGICAL), VCIV manufactured with the current manufacturing process (VCIV current) (BIOLOGICAL), Fluzone®, licensed trivalent influenza vaccine (TIV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01773928?
This trial is sponsored by Alachua Government Services, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.